**Drug Discovery Symposium**

Bloomberg Lecture Hall  
Institute for Advanced Study, Princeton, NJ

Hosted by:  
THE SIMONS CENTER FOR SYSTEMS BIOLOGY  
Arnold J. Levine, Professor

With Generous Support from  
Devon Park Bioventures  
Venrock

**SYMPOSIUM SCHEDULE**

**Wednesday, September 17, 2008**

8:15 a.m. - 8:55 a.m. **COFFEE AVAILABLE** - Bloomberg Hall Biology Atrium

8:55 a.m. - 9:00 a.m. **Welcoming Remarks**  
Arnold J. Levine, Institute for Advanced Study

9:00 a.m. - 9:40 a.m. **Michael C. Venuti, BioSeek, Inc.**  
*Picking Winners at the Discovery Stage of Drug Development*

9:40 a.m. - 10:20 a.m. **Julian Adams, Infinity Pharmaceuticals, Inc.**  
*Development of the Novel Hsp90 Inhibitor IPI-504 and Insights into the Tumor Cell Selectivity of Hsp90 Inhibitors*

10:20 a.m. - 10:40 a.m. **COFFEE BREAK** - Bloomberg Hall Biology Atrium

10:40 a.m. - 11:20 a.m. **Neal Rosen, Memorial Sloan-Kettering Cancer Center**  
*Mechanism-Based Combination Therapy*

11:20 a.m. - 12:00 p.m. **George D. Demetri, Dana-Farber Cancer Institute, Harvard Medical School and Ludwig Institute for Cancer Research**  
*Targeting Validated Oncogenic Mechanisms to Improve Anticancer Drug Discovery and Development*

12:00 p.m. - 12:40 p.m. **Matthew L. Meyerson, Dana-Farber Cancer Institute, Harvard Medical School & Broad Institute of Harvard and MIT**  
*Genomic Alterations in Human Cancer*

12:40 p.m. - 2:00 p.m. **LUNCH** – Available in Institute Dining Hall
Drug Discovery Symposium

Wednesday, September 17, 2008 (continued)

2:00 p.m. - 2:40 p.m. Todd Golub, Broad Institute, Dana-Farber Cancer Institute, Harvard Medical School and HHMI
Signatures for Small Molecule Discovery

2:40 p.m. - 3:20 p.m. Alexei Vazquez, Institute for Advanced Study
Identifying Single Nucleotide Polymorphisms that Affect Human Cancer Using the NCI60 Human Tumor Cell Line Anticancer Drug Screen

3:20 p.m. - 3:40 p.m. AFTERNOON TEA BREAK - Fuld Hall Common Room

3:40 p.m. - 4:20 p.m. Charles L. Sawyers, Memorial Sloan-Kettering Cancer Center and HHMI
Overcoming Resistance to Molecularly Targeted Therapy

4:20 p.m. - 5:00 p.m. Daniel A. Haber, Massachusetts General Hospital Cancer Center

5:00 p.m. - 6:00 p.m. PANEL DISCUSSION
Arnold J. Levine - Moderator
Stephen Friend, Merck & Co., Inc.
William N. Hait, Johnson & Johnson
Robert Kramer, Bristol-Myers Squibb
Allen I. Oliff, GlaxoSmithKline